Predictors of Improvement in PFS With Maintenance PARP Inhibitor Therapy in Women With Platinum-Sensitive, Recurrent Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Molecular and Clinical Predictors of Improvement in Progression-Free Survival With Maintenance PARP Inhibitor Therapy in Women With Platinum-Sensitive, Recurrent Ovarian Cancer: A Meta-Analysis
Cancer 2021 Mar 19;[EPub Ahead of Print], CK Lee, ML Friedlander, A Tjokrowidjaja, JA Ledermann, RL Coleman, MR Mirza, UA Matulonis, E Pujade-Lauraine, R Bloomfield, S Goble, P Wang, RM Glasspool, CL ScottFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.